Regeneron COPD Drug Shows 27% Reduction in Phase 3 Trial, Mixed Results | REGN Stock News

TL;DR


Summary:
- This article discusses the results of a clinical trial for a new drug called itepekimab, which is being developed to treat chronic obstructive pulmonary disease (COPD).
- The trial found that itepekimab met its primary endpoint, meaning it was effective in improving lung function in patients with COPD.
- COPD is a chronic lung disease that makes it difficult to breathe, and this new drug could potentially help many people who suffer from this condition.

Like summarized versions? Support us on Patreon!